# A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer

> **NCT00548548** · PHASE3 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 774 (actual)

## Conditions studied

- Adenocarcinoma

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Capecitabine
- **DRUG:** Cisplatin
- **DRUG:** Placebo
- **DRUG:** 5-fluorouracil

## Key facts

- **NCT ID:** NCT00548548
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2009-11
- **Final completion:** 2013-11
- **Target enrollment:** 774 (ACTUAL)
- **Last updated:** 2017-06-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00548548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00548548, "A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00548548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*